SVB Wealth LLC Has $10.99 Million Position in Abbott Laboratories $ABT

SVB Wealth LLC cut its stake in shares of Abbott Laboratories (NYSE:ABT) by 8.2% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 82,085 shares of the healthcare product maker’s stock after selling 7,371 shares during the period. SVB Wealth LLC’s holdings in Abbott Laboratories were worth $10,994,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Norges Bank purchased a new position in Abbott Laboratories in the second quarter valued at about $3,026,180,000. Laurel Wealth Advisors LLC lifted its holdings in shares of Abbott Laboratories by 13,347.0% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 6,056,934 shares of the healthcare product maker’s stock valued at $823,804,000 after buying an additional 6,011,891 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Abbott Laboratories by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock valued at $23,502,644,000 after buying an additional 2,977,715 shares in the last quarter. First Trust Advisors LP increased its holdings in Abbott Laboratories by 180.7% in the second quarter. First Trust Advisors LP now owns 3,063,443 shares of the healthcare product maker’s stock worth $416,659,000 after buying an additional 1,972,097 shares during the last quarter. Finally, TD Asset Management Inc raised its position in Abbott Laboratories by 98.6% during the second quarter. TD Asset Management Inc now owns 3,467,896 shares of the healthcare product maker’s stock valued at $471,669,000 after acquiring an additional 1,721,523 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Analysts Set New Price Targets

ABT has been the subject of several recent research reports. Daiwa Securities Group decreased their target price on shares of Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a research report on Friday, January 30th. Sanford C. Bernstein decreased their price objective on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Royal Bank Of Canada cut their target price on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Leerink Partners decreased their price target on Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a research note on Friday, January 30th. Finally, Evercore cut their price objective on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $137.05.

Abbott Laboratories Stock Performance

ABT opened at $111.11 on Tuesday. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23. The stock’s 50 day moving average price is $120.52 and its two-hundred day moving average price is $126.80. The firm has a market capitalization of $193.21 billion, a P/E ratio of 29.87, a price-to-earnings-growth ratio of 1.76 and a beta of 0.75. Abbott Laboratories has a 12-month low of $105.27 and a 12-month high of $141.23.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The business had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. During the same quarter last year, the company posted $1.34 earnings per share. Abbott Laboratories’s quarterly revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, equities analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Thursday, January 15th will be given a dividend of $0.63 per share. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.59. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Thursday, January 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 67.74%.

Insider Buying and Selling at Abbott Laboratories

In other news, Director Daniel J. Starks bought 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 4th. The shares were acquired at an average cost of $108.73 per share, with a total value of $1,087,300.00. Following the completion of the transaction, the director directly owned 6,738,817 shares in the company, valued at $732,711,572.41. This represents a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.